Loss of tumor suppressor gene function in human cancer: an overview

LH Wang, CF Wu, N Rajasekaran… - Cellular Physiology and …, 2019 - karger.com
Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two
types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research …

The role of DNA methylation in cancer development.

MW Luczak, PP Jagodziński - Folia histochemica et …, 2006 - journals.viamedica.pl
Epigenetic modifications include DNA methylation and covalent modification of histones.
These alterations are reversible but very stable and exert a significant impact on the …

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

A Stengel, W Kern, T Haferlach, M Meggendorfer… - Leukemia, 2017 - nature.com
Alterations in TP53 have been described in many cancer types including hematological
neoplasms. We aimed at comparing TP53 mutations (mut) and deletions (del) in a large …

Structure and activity of putative intronic miRNA promoters

AM Monteys, RM Spengler, J Wan, L Tecedor… - Rna, 2010 - rnajournal.cshlp.org
MicroRNAs (miRNAs) are RNA sequences of∼ 22 nucleotides that mediate post-
transcriptional regulation of specific mRNAs. miRNA sequences are dispersed throughout …

[图书][B] The toxicology of fishes

RT Di Giulio, DE Hinton - 2008 - taylorfrancis.com
When looking for a book on fish toxicology, you might find one that discusses the
biochemical and molecular aspects, or one that focuses aquatic toxicology in general. You …

Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies

ZY Xu-Monette, LJ Medeiros, Y Li… - Blood, The Journal …, 2012 - ashpublications.org
Mutations of the TP53 gene and dysregulation of the TP53 pathway are important in the
pathogenesis of many human cancers, including lymphomas. Tumor suppression by p53 …

TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis

A Stengel, S Schnittger, S Weissmann… - Blood, The Journal …, 2014 - ashpublications.org
TP53 is the most extensively studied gene in cancer. However, data on frequency and the
prognostic impact of TP53 mutations in acute lymphoblastic leukemia (ALL) remain scarce …

The paradigm of drug resistance in cancer: an epigenetic perspective

S Adhikari, A Bhattacharya, S Adhikary… - Bioscience …, 2022 - portlandpress.com
Innate and acquired resistance towards the conventional therapeutic regimen imposes a
significant challenge for the successful management of cancer for decades. In patients with …

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing

H Isomoto, JL Mott, S Kobayashi, NW Werneburg… - Gastroenterology, 2007 - Elsevier
Background & Aims: Interleukin 6 (IL-6)-mediated signal transducers and activators of
transcription 3 (STAT-3) phosphorylation (activation) is aberrantly sustained in …

Targeting p53 by small molecules in hematological malignancies

MN Saha, L Qiu, H Chang - Journal of hematology & oncology, 2013 - Springer
Abstract p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A
breakthrough in cancer research came from the discovery of the drugs which are capable of …